Disclosure of material issue

Aurobindo Pharma's Board has approved the transfer of its domestic branded generic pharmaceutical formulations business to its wholly-owned subsidiary, Auropharm Limited. **Issue:** Aurobindo Pharma is transferring its domestic branded generic pharma business, a relatively small part of its overall operations, to a subsidiary. * The business contributed about 175.34 Cr to consolidated turnover (0.55%) and 148.14 Cr to consolidated net worth (0.45%) in the last financial year. * The standalone revenue of the transferred business was 175.34 Cr for the year ended March 31, 2025, compared to Aurobindo Pharma's standalone revenue of 10,933.3 Cr. **Possible Impact:** This internal restructuring aims to streamline and accelerate the company’s domestic business for faster growth and greater operational efficiency.

Since it's a transfer to a wholly-owned subsidiary, there is no impact on the consolidated financials of Aurobindo Pharma. **Company’s Response/Mitigation Plan:** The company is executing a slump sale for a lumpsum consideration of 143.21 Cr.

This move consolidates the domestic pharmaceuticals business under Auropharm Limited, which already manages other non-oncology formulations business, allowing for a more focused approach and expansion.

The sale is expected to complete within 90-120 days.